Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMKELDI vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some Amp C enzymes.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
FDA-approved: Treatment of complicated urinary tract infections including pyelonephritis in adults,FDA-approved: Treatment of complicated intra-abdominal infections in adults,FDA-approved: Treatment of hospital-acquired and ventilator-associated bacterial pneumonia in adults,Off-label: Treatment of bacteremia due to susceptible gram-negative pathogens,Off-label: Treatment of infections due to carbapenem-resistant Enterobacteriaceae (CRE)
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
10 mg orally once daily
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (Cr Cl 30-50 m L/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Imipenem is metabolized in the kidney by dehydropeptidase I. Cilastatin is a competitive inhibitor of this enzyme and is also partially metabolized renally. Relebactam is minimally metabolized, primarily eliminated unchanged in urine. The combination has a half-life of approximately 1 hour. No significant hepatic metabolism.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
98% bound to serum albumin.
47% bound to human plasma proteins, primarily albumin.
0.2 L/kg (approx. 14 L in 70 kg adult). Low Vd indicates distribution primarily in extracellular fluid and plasma, consistent with high protein binding and limited tissue penetration.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Oral: 85% (high bioavailability, minimal first-pass metabolism).
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min).
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Child-Pugh A: No dose adjustment. Child-Pugh B: 5 mg orally once daily. Child-Pugh C: Not recommended.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy not established in pediatric patients.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended; consider starting at the lower end of the dosing range due to potential age-related renal impairment.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
None. There is no FDA boxed warning for Imkelde.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity reactions (including anaphylaxis) may occur. Cross-allergenicity with other beta-lactams.,Seizures: Higher risk in patients with CNS disorders or renal impairment. Dose adjustment for renal function is required.,Clostridioides difficile-associated diarrhea (CDAD): Can range from mild diarrhea to fatal colitis.,Renal impairment: Dose adjustment necessary; monitor renal function.,Development of drug-resistant bacteria: Overuse may promote resistance.,Interference with laboratory tests: May cause positive direct Coombs test.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Known hypersensitivity to any component of Imkelde (imipenem, cilastatin, relebactam) or other beta-lactam antibiotics.,Contraindicated in patients with severe hypersensitivity (e.g., anaphylaxis) to any beta-lactam.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Grapefruit and grapefruit juice increase drug exposure and should be avoided. High-fat meals may slightly increase absorption, but consistent timing with meals is recommended.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
First trimester: No adequate human data; animal studies show fetal anomalies at maternal toxic doses. Second and third trimesters: Risk of fetal hypoglycemia and hyperinsulinemia due to KATP channel blockade; avoid unless maternal benefit outweighs risk.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
Excreted in breast milk; M/P ratio unknown. Potential for infant hypoglycemia; use with caution and monitor infant blood glucose.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No specific dose adjustments required; pharmacokinetics unchanged in pregnancy based on limited data. Dose adjustment may be needed for renal function changes.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Monitor renal function closely; dose adjustment required for Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors unless benefit outweighs risk. Administer with food to reduce GI upset.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Take with meals to decrease stomach upset.,Avoid grapefruit juice during treatment.,Report any signs of allergic reaction, such as rash or difficulty breathing, immediately.,Do not drive or operate machinery if you experience dizziness or drowsiness.,Stay hydrated and inform your doctor of any changes in urine output.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMKELDI vs CLOLAR, answered by our medical review team.
IMKELDI is a Antineoplastic Agent that works by Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some Amp C enzymes.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMKELDI and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMKELDI is: 10 mg orally once daily. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMKELDI and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMKELDI is classified as Category C. First trimester: No adequate human data; animal studies show fetal anomalies at maternal toxic doses. Second and third trimesters: Risk of fetal hypoglycemia and hyperinsulinemia d. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.